Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Fullarton

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysisCarlo Palmieri, John R Fullarton, Janet Brown
Journal of Pain and Symptom Management|February 6, 2013
Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trialsRavi Jandhyala, John R Fullarton, Michael I Bennett
Journal of Pain and Symptom Management|May 10, 2014
Authors' reply to DavisRavi Jandhyala, John R Fullarton, Michael I Bennett
Current Medical Research and Opinion|August 18, 2021
Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysisKristine Paridaens, John R Fullarton, Simon P L Travis
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|July 27, 2023
Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitisKristine Paridaens, John R Fullarton, Simon P L Travis
Journal of Perinatal Medicine|October 25, 2012
The evolution of risk factors for respiratory syncytial virus-related hospitalisation in infants born at 32-35 weeks' gestational age: time-based analysis using data from the FLIP-2 studyXavier Carbonell, John R Fullarton, Katherine L Gooch, et al.
Current Medical Research and Opinion|April 5, 2021
Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infantsBosco Paes, John R Fullarton, Barry S Rodgers-Gray, et al.
The Pediatric Infectious Disease Journal|December 18, 2009
Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational ageLone G Stensballe, John R Fullarton, Xavier Carbonell-Estrany, et al.
Journal of Perinatal Medicine|March 20, 2010
Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestationXavier Carbonell-Estrany, Eric A F Simões, John R Fullarton, et al.
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|May 22, 2010
European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian dataEric A F Simões, Xavier Carbonell-Estrany, John R Fullarton, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysisCarlo Palmieri, John R Fullarton, Janet Brown
Journal of Pain and Symptom Management|February 6, 2013
Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trialsRavi Jandhyala, John R Fullarton, Michael I Bennett
Journal of Pain and Symptom Management|May 10, 2014
Authors' reply to DavisRavi Jandhyala, John R Fullarton, Michael I Bennett
Current Medical Research and Opinion|August 18, 2021
Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysisKristine Paridaens, John R Fullarton, Simon P L Travis
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|July 27, 2023
Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitisKristine Paridaens, John R Fullarton, Simon P L Travis
Journal of Perinatal Medicine|October 25, 2012
The evolution of risk factors for respiratory syncytial virus-related hospitalisation in infants born at 32-35 weeks' gestational age: time-based analysis using data from the FLIP-2 studyXavier Carbonell, John R Fullarton, Katherine L Gooch, et al.
Current Medical Research and Opinion|April 5, 2021
Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infantsBosco Paes, John R Fullarton, Barry S Rodgers-Gray, et al.
The Pediatric Infectious Disease Journal|December 18, 2009
Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational ageLone G Stensballe, John R Fullarton, Xavier Carbonell-Estrany, et al.
Journal of Perinatal Medicine|March 20, 2010
Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestationXavier Carbonell-Estrany, Eric A F Simões, John R Fullarton, et al.
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|May 22, 2010
European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian dataEric A F Simões, Xavier Carbonell-Estrany, John R Fullarton, et al.
Pageof 3